Equity MRK
Friday, July 20, 2018   
Adani Ports  369.90    (0.20%)
 
Asian Paints  1396.90    (-0.18%)
 
Axis Bank  534.45    (1.36%)
 
Bajaj Auto  2841.10    (-8.73%)
 
Bharti Airtel  345.55    (0.14%)
 
Coal India  263.15    (0.63%)
 
H D F C  1975.20    (-0.71%)
 
HDFC Bank  2190.10    (0.20%)
 
Hero Motocorp  3373.15    (-2.48%)
 
Hind. Unilever  1656.20    (0.49%)
 
ICICI Bank  266.00    (1.84%)
 
IndusInd Bank  1902.30    (0.70%)
 
Infosys  1348.35    (2.42%)
 
ITC  273.45    (0.20%)
 
Kotak Mah. Ban...  1333.45    (-1.24%)
 
Larsen & Toubr...  1269.35    (1.10%)
 
M & M  909.55    (-0.12%)
 
Maruti Suzuki  9386.75    (-0.02%)
 
NTPC  155.30    (0.52%)
 
O N G C  157.85    (-2.20%)
 
Power Grid Cor...  176.20    (-0.59%)
 
Reliance Inds.  1128.55    (2.23%)
 
St Bk of India  260.95    (0.31%)
 
Sun Pharma.Ind...  559.90    (2.72%)
 
Tata Motors  253.40    (0.38%)
 
Tata Motors-DV...  140.80    (0.82%)
 
Tata Steel  503.45    (0.74%)
 
TCS  1995.95    (0.73%)
 
Vedanta  202.60    (-2.74%)
 
Wipro  283.05    (-0.77%)
 
Yes Bank  386.65    (-1.16%)
 
Market Menu
plusminDaily Market Tracker
plusminNews
Corporate Information
Corporate Actions
Other Markets
Close
You are here : Equity | News | Corporate News
Cadila Healthcare's JV facility of Zydus Hopsira Oncology receives EIR from USFDA
(13:08, 12 Jul 2018)
Cadila Healthcare announced that the manufacturing facility of Zydus Hopsira Oncology, a 50:50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is closed and states that theinspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from 5 to 12 April, 2018.

Powered by Capital Market - Live News